Therapeutic potential of curcumin in digestive diseases

World Journal of Gastroenterology

Volumn 19, Issue 48, 2013, Pages 9256-9270

  Dulbecco, Pietro ^a   Savarino, Vincenzo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Curcumin; Curcumin bioavailability; Curcumin phythosome; Digestive disorders

Indexed keywords

CHOLAGOGUE; CURCUMIN; DRUG METABOLITE; GLYCYRRHETINIC ACID PHOSPHOLIPID COMPLEX; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 21; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MERIVA; MITOGEN ACTIVATED PROTEIN KINASE; STAT PROTEIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CELL PROLIFERATION; CLINICAL DISEASE ACTIVITY INDEX; COLORECTAL CANCER; CURCUMA LONGA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; GENE EXPRESSION; HUMAN; INFLAMMATORY BOWEL DISEASE; LIVER DISEASE; LIVER PROTECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; TISSUE DISTRIBUTION; TUMOR GROWTH;

CURCUMIN; CURCUMIN BIOAVAILABILITY; CURCUMIN-PHYTHOSOME; DIGESTIVE DISORDERS;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHEMISTRY, PHARMACEUTICAL; CURCUMA; CURCUMIN; DIGESTIVE SYSTEM DISEASES; GASTROINTESTINAL AGENTS; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; TREATMENT OUTCOME;

EID: 84891434344     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i48.9256     Document Type: Review

References (107)

1. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991; 57: 1-7 [PMID: 2062949 DOI: 10.1055/ s-2006-960004]
2. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363-398 [PMID: 12680238]
3. Kita T, Imai S, Sawada H, Kumagai H, Seto H. The biosynthetic pathway of curcuminoid in turmeric (Curcuma longa) as revealed by 13C-labeled precursors. Biosci Biotechnol Biochem 2008; 72: 1789-1798 [PMID: 18603793 DOI: 10.1271/ bbb.80075]
4. Balasubramanian K. Molecular orbital basis for yellow curry spice curcumin's prevention of Alzheimer's disease. J Agric Food Chem 2006; 54: 3512-3520 [PMID: 19127718 DOI:10.1021/jf0603533]
5. Priyadarsini KI, Maity DK, Naik GH, Kumar MS, Unnikrishnan MK, Satav JG, Mohan H. Role of phenolic O-H and methylene hydrogen on the free radical reactions and antioxidant activity of curcumin. Free Radic Biol Med 2003; 35: 475-484 [PMID: 12927597 DOI: 10.1016/ S0891-5849(03)00325-3]
6. Wahlström B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 1978; 43: 86-92 [PMID: 696348 DOI: 10.1111/j.1600-0773.1978.tb02240.x]
7. Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology 1980; 16: 259-265 [PMID: 7423534 DOI: 10.1016/0300-483X(80)90122-5]
8. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998; 64: 353-356 [PMID: 9619120 DOI: 10.1055/s-2006-957450]
9. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 2001; 21: 2895-2900 [PMID: 11712783]
10. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 6847-6854 [PMID: 15501961 DOI: 10.1158/1078-0432.CCR-04-0744]
11. Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 853: 183-189 [PMID: 17400527 DOI:10.1016/j.jchromb.2007.03.010]
12. Ravindranath V, Chandrasekhara N. Metabolism of curcumin--studies with [3H]curcumin. Toxicology 1981; 22: 337-344 [PMID: 7342372 DOI: 10.1016/0300-483X(81)90027-5]
13. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ, Berry DP. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004; 90: 1011-1015 [PMID: 14997198 DOI: 10.1038/ sj.bjc.6601623]
14. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005; 14: 120-125 [PMID: 15668484]
15. Hoehle SI, Pfeiffer E, Sólyom AM, Metzler M. Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver. J Agric Food Chem 2006; 54: 756-764 [PMID: 16448179 DOI: 10.1021/jf058146a]
16. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 1978; 8: 761-768 [PMID: 726520 DOI: 10.3109/00498257809069589]
17. Asai A, Miyazawa T. Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci 2000; 67: 2785-2793 [PMID: 11105995 DOI: 10.1016/S0024-3205(00)00868-7]
18. Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, Badmaev V, Aggarwal BB. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROSindependent mechanism. Carcinogenesis 2007; 28: 1765-1773 [PMID: 17522064 DOI: 10.1093/carcin/bgm123]
19. Pfeiffer E, Hoehle SI, Walch SG, Riess A, Sólyom AM, Metzler M. Curcuminoids form reactive glucuronides in vitro. J Agric Food Chem 2007; 55: 538-544 [PMID: 17227090 DOI:10.1021/jf0623283]
20. Kim JM, Araki S, Kim DJ, Park CB, Takasuka N, Baba-Toriyama H, Ota T, Nir Z, Khachik F, Shimidzu N, Tanaka Y, Osawa T, Uraji T, Murakoshi M, Nishino H, Tsuda H. Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-dimethylhydrazine initiation. Carcinogenesis 1998; 19: 81-85 [PMID: 9472697 DOI:10.1093/carcin/19.1.81]
21. Pari L, Murugan P. Tetrahydrocurcumin: effect on chloroquine-mediated oxidative damage in rat kidney. Basic Clin Pharmacol Toxicol 2006; 99: 329-334 [PMID: 17076682 DOI:10.1111/j.1742-7843.2006.pto_503.x]
22. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7: 1894-1900 [PMID: 11448902]
23. Bisht S, Maitra A. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr Drug Discov Technol 2009; 6: 192-199 [PMID: 19496751 DOI: 10.2174/1570 16309789054933]
24. Semalty A, Semalty M, Rawat MS, Franceschi F. Supramolecular phospholipids-polyphenolics interactions: the PHYTOSOME strategy to improve the bioavailability of phytochemicals. Fitoterapia 2010; 81: 306-314 [PMID: 19919847 DOI: 10.1016/j.fitote.2009.11.001]
25. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 2007; 60: 171-177 [PMID: 17051370 DOI: 10.1007/s00280-006-0355-x]
26. Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S, Dixon BM. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 2011; 74: 664-669 [PMID: 21413691 DOI:10.1021/np1007262]
27. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6: 10 [PMID: 16545122 DOI:10.1186/1472-6882-6-10]
28. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL, Brenner DE. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 2011; 4: 354-364 [PMID: 21372035 DOI:10.1158/1940-6207.CAPR-10-0098]
29. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as " Curecumin": from kitchen to clinic. Biochem Pharmacol 2008; 75: 787-809 [PMID: 17900536]
30. Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 1999; 39: 41-47 [PMID: 10051376 DOI: 10.1006/phrs.1998.0404]
31. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: downregulation of COX-2 and iNOS through suppression of NFkappa B activation. Mutat Res 2001; 480-481: 243-268 [PMID: 11506818]
32. Satou R, Miyata K, Katsurada A, Navar LG, Kobori H. Tumor necrosis factor-{alpha} suppresses angiotensinogen expression through formation of a p50/p50 homodimer in human renal proximal tubular cells. Am J Physiol Cell Physiol 2010; 299: C750-C759 [PMID: 20592241 DOI: 10.1152/ajpcell.00078.2010]
33. Brasier AR. The NF-kappaB regulatory network. Cardiovasc Toxicol 2006; 6: 111-130 [PMID: 17303919 DOI: 10.1385/ CT:6:2:111]
34. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, Sartor RB. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 1999; 163: 3474-3483 [PMID: 10477620]
35. Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney AH. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 1991; 51: 813-819 [PMID: 1899046]
36. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008; 267: 133-164 [PMID: 18462866 DOI: 10.1016/j.canlet.2008.03.025]
37. Nowell PC. Tumor progression: a brief historical perspective. Semin Cancer Biol 2002; 12: 261-266 [PMID: 12147207 DOI: 10.1016/S1044-579X(02)00012-3]
38. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-217 [PMID: 15766659]
39. Carlier-Mercier L, Fontaine JL, Boccon-Gibod L, Girardet JP, Josset P, Gouraud F, Pinturier MF. A rare cause of neonatal exudative enteropathy: congenital Langerhans cell histiocytosis (histiocytosis X). Arch Fr Pediatr 1992; 49: 199-201 [PMID: 1610278 DOI: 10.1016/j.mrfmmm.2005.04.019]
40. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004; 14: 433-439 [PMID: 15489136 DOI: 10.1016/j.semcancer.2004.06.006]
41. St-Pierre Y, Couillard J, Van Themsche C. Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases. Expert Opin Ther Targets 2004; 8: 473-489 [PMID: 15469396 DOI: 10.1517/14728222.8.5.473]
42. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest 2005; 115: 2625-2632 [PMID: 16200195 DOI:10.1172/JCI26322]
43. Sumanont Y, Murakami Y, Tohda M, Vajragupta O, Matsumoto K, Watanabe H. Evaluation of the nitric oxide radical scavenging activity of manganese complexes of curcumin and its derivative. Biol Pharm Bull 2004; 27: 170-173 [PMID: 14758027 DOI: 10.1248/bpb.27.170]
44. Gao X, Kuo J, Jiang H, Deeb D, Liu Y, Divine G, Chapman RA, Dulchavsky SA, Gautam SC. Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro. Biochem Pharmacol 2004; 68: 51-61 [PMID: 15183117 DOI: 10.1016/j.bcp.2004.03.015]
45. Grandjean-Laquerriere A, Gangloff SC, Le Naour R, Trentesaux C, Hornebeck W, Guenounou M. Relative contribution of NF-kappaB and AP-1 in the modulation by curcumin and pyrrolidine dithiocarbamate of the UVB-induced cytokine expression by keratinocytes. Cytokine 2002; 18: 168-177 [PMID: 12126654 DOI: 10.1006/cyto.2002.0888]
46. Feng R, Lu Y, Bowman LL, Qian Y, Castranova V, Ding M. Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J Biol Chem 2005; 280: 27888-27895 [PMID: 15944151 DOI: 10.1074/jbc.M503347200]
47. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 2004; 111: 679-692 [PMID: 15252836 DOI: 10.1002/ijc.20333]
48. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 2005; 224: 53-65 [PMID: 15911101 DOI:10.1016/j.canlet.2004.10.051]
49. Lee JS, Surh YJ. Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 2005; 224: 171-184 [PMID: 15914268 DOI: 10.1016/j.canlet.2004.09.042]
50. Kim JH, Lee KW, Lee MW, Lee HJ, Kim SH, Surh YJ. Hirsutenone inhibits phorbol ester-induced upregulation of COX-2 and MMP-9 in cultured human mammary epithelial cells: NF-kappaB as a potential molecular target. FEBS Lett 2006; 580: 385-392 [PMID: 16380122 DOI: 10.1016/ j.febslet.2005.12.015]
51. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001; 172: 111-118 [PMID: 11566484 DOI: 10.1016/S0304-3835(01)00655-3]
52. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001; 7: 14-23 [PMID: 11349215 DOI: 10.1007/ BF03032599]
53. Woo MS, Jung SH, Kim SY, Hyun JW, Ko KH, Kim WK, Kim HS. Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochem Biophys Res Commun 2005; 335: 1017-1025 [PMID: 16102725 DOI: 10.1016/j.bbrc.2005.07.174]
54. Philip S, Bulbule A, Kundu GC. Matrix metalloproteinase-2: mechanism and regulation of NF-kappaB-mediated activation and its role in cell motility and ECM-invasion. Glycoconj J 2004; 21: 429-441 [PMID: 15750784 DOI: 10.1007/ s10719-004-5533-7]
55. O'Hanlon DM, Fitzsimons H, Lynch J, Tormey S, Malone C, Given HF. Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer 2002; 38: 2252-2257 [PMID: 12441261 DOI: 10.1016/S0959-8049(02) 00218-6]
56. Lee CW, Lin WN, Lin CC, Luo SF, Wang JS, Pouyssegur J, Yang CM. Transcriptional regulation of VCAM-1 expression by tumor necrosis factor-alpha in human tracheal smooth muscle cells: involvement of MAPKs, NF-kappaB, p300, and histone acetylation. J Cell Physiol 2006; 207: 174-186 [PMID: 16288471 DOI: 10.1002/jcp.20549]
57. Thangapazham RL, Sharma A, Maheshwari RK. Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J 2006; 8: E443-E449 [PMID: 17025261 DOI: 10.1208/ aapsj080352]
58. Radhakrishna Pillai G, Srivastava AS, Hassanein TI, Chauhan DP, Carrier E. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett 2004; 208: 163-170 [PMID: 15142674 DOI: 10.1016/j.canlet.2]
59. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, Sung B, Ichikawa H. Targeting signaltransducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 2006; 1091: 151-169 [PMID: 17341611 DOI:10.1196/annals.1378.063]
60. Darnell JE. STATs and gene regulation. Science 1997; 277: 1630-1635 [PMID: 9287210 DOI: 10.1126/science.277.5332.1630]
61. Dell'Albani P, Santangelo R, Torrisi L, Nicoletti VG, de Vellis J, Giuffrida Stella AM. JAK/STAT signaling pathway mediates cytokine-induced iNOS expression in primary astroglial cell cultures. J Neurosci Res 2001; 65: 417-424 [PMID: 11536325 DOI: 10.1002/jnr.1169]
62. Kovarik P, Mangold M, Ramsauer K, Heidari H, Steinborn R, Zotter A, Levy DE, Müller M, Decker T. Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression. EMBO J 2001; 20: 91-100 [PMID: 11226159 DOI: 10.1093/emboj/20.1.91]
63. Cull VS, Tilbrook PA, Bartlett EJ, Brekalo NL, James CM. Type I interferon differential therapy for erythroleukemia: specificity of STAT activation. Blood 2003; 101: 2727-2735 [PMID: 12446459 DOI: 10.1182/blood-2002-05-1521]
64. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 2001; 19: 378-387 [PMID: 11553846 DOI: 10.1634/stemcells.19-5-378]
65. Shishodia S, Chaturvedi MM, Aggarwal BB. Role of curcumin in cancer therapy. Curr Probl Cancer 2007; 31: 243-305 [PMID: 17645940 DOI: 10.1016/j.currproblcancer.2007.04.001]
66. Rajasingh J, Raikwar HP, Muthian G, Johnson C, Bright JJ. Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAKSTAT pathway in T cell leukemia. Biochem Biophys Res Commun 2006; 340: 359-368 [PMID: 16364242 DOI: 10.1016/ j.bbrc.2005.12.014]
67. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171: 3863-3871 [PMID: 14500688]
68. Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R, Finke J. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 1996; 88: 809-816 [PMID: 8704235]
69. Mackenzie GG, Queisser N, Wolfson ML, Fraga CG, Adamo AM, Oteiza PI. Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells. Int J Cancer 2008; 123: 56-65 [PMID: 18386790 DOI:10.1002/ijc.23477]
70. Seo JH, Jeong KJ, Oh WJ, Sul HJ, Sohn JS, Kim YK, Cho do Y, Kang JK, Park CG, Lee HY. Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. Cancer Lett 2010; 288: 50-56 [PMID: 19647363 DOI: 10.1016/j.canlet.2009.06.023]
71. Egwuagu CE. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine 2009; 47: 149-156 [PMID: 19648026 DOI: 10.1016/j.cyto.2009.07.003]
72. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429 [PMID: 12167685 DOI: 10.1056/ NEJM199109263251306]
73. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-1610 [PMID: 15168370 DOI: 10.1053/ j.gastro.2004.02.070]
74. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-962 [PMID: 18587394 DOI: 10.1038/ng.175]
75. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449: 819-826 [PMID: 17943118 DOI: 10.1038/nature06246]
76. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006; 311: 17-58 [PMID: 17048704 DOI: 10.1007/3-540-32636-7_2]
77. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282: 20059-20063 [PMID: 17502367 DOI: 10.1074/jbc.R700016200]
78. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5: 521-531 [PMID: 15999093 DOI: 10.1038/nri1648]
79. Lovato P, Brender C, Agnholt J, Kelsen J, Kaltoft K, Svejgaard A, Eriksen KW, Woetmann A, Ødum N. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 2003; 278: 16777-16781 [PMID: 12615922 DOI: 10.1074/jbc.M207999200]
80. Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 1998; 161: 4652-4660 [PMID: 9794394]
81. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med 2008; 263: 591-596 [PMID: 18479258 DOI: 10.1111/j.1365-2796.2008.01953.x]
82. Sugimoto K. Role of STAT3 in inflammatory bowel disease. World J Gastroenterol 2008; 14: 5110-5114 [PMID: 18777586 DOI: 10.3748/wjg.14.5110]
83. Afif W, Loftus EV. Safety profile of IBD therapeutics: infectious risks. Med Clin North Am 2010; 94: 115-133 [PMID: 19944801 DOI: 10.1016/j.mcna.2009.08.016]
84. Hilsden RJ, Verhoef MJ, Rasmussen H, Porcino A, DeBruyn JC. Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 655-662 [PMID: 20848543 DOI: 10.1002/ibd.21360]
85. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005; 50: 2191-2193 [PMID: 16240238 DOI: 10.1007/s10620-005-3032-8]
86. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 1502-1506 [PMID: 17101300 DOI:10.1016/j.cgh.2006.08.008]
87. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, Giardiello FM. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006; 4: 1035-1038 [PMID: 16757216 DOI: 10.1016/j.cgh.2006.03.020]
88. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231 [PMID: 11961152 DOI: 10.1056/NEJMra011775]
89. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384 [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008]
90. Rivera-Espinoza Y, Muriel P. Pharmacological actions of curcumin in liver diseases or damage. Liver Int 2009; 29: 1457-1466 [PMID: 19811613 DOI: 10.1111/j.1478-3231.2009.02086.x]
91. Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. Am J Physiol Gastrointest Liver Physiol 2003; 284: G321-G327 [PMID: 12388178 DOI: 10.1152/ajpgi.00230.2002]
92. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99 [PMID: 16563223 DOI: 10.1111/j.1582-4934.2006. tb00292.x]
93. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013; 15: 195-218 [PMID: 23143785 DOI: 10.1208/s12248-012-9432-8]
94. Gaedeke J, Noble NA, Border WA. Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis through up-regulation of heme oxygenase 1. Kidney Int 2005; 68: 2042-2049 [PMID: 16221204 DOI: 10.1111/j.1523-1755.2004.00713.x]
95. Kang HC, Nan JX, Park PH, Kim JY, Lee SH, Woo SW, Zhao YZ, Park EJ, Sohn DH. Curcumin inhibits collagen synthesis and hepatic stellate cell activation in-vivo and in-vitro. J Pharm Pharmacol 2002; 54: 119-126 [PMID: 11829122 DOI:10.1211/0022357021771823]
96. Miquel J, Bernd A, Sempere JM, Díaz-Alperi J, Ramírez A. The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Arch Gerontol Geriatr 2002; 34: 37-46 [PMID: 14764309 DOI: 10.1016/ S0167-4943(01)00194-7]
97. Iqbal M, Sharma SD, Okazaki Y, Fujisawa M, Okada S. Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. Pharmacol Toxicol 2003; 92: 33-38 [PMID: 12710595 DOI: 10.1034/j.1600-0773.2003.920106.x]
98. Ak T, Gülçin I. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact 2008; 174: 27-37 [PMID: 18547552 DOI: 10.1016/j.cbi.2008.05.003]
99. Motterlini R, Foresti R, Bassi R, Green CJ. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 2000; 28: 1303-1312 [PMID: 10889462 DOI: 10.1016/S0891-5849(00)00294-X]
100. Savarino E, Zentilin P, Savarino V. NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol 2013; 10: 371-380 [PMID: 23528345 DOI:10.1038/nrgastro.2013.50]
101. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut 2008; 57: 674-683 [PMID: 18079285 DOI: 10.1136/gut.2007.127886]
102. Caterina MJ, Rosen TA, Tominaga M, Brake AJ, Julius D. A capsaicin-receptor homologue with a high threshold for noxious heat. Nature 1999; 398: 436-441 [PMID: 10201375 DOI: 10.1038/18906]
103. Zhi L, Dong L, Kong D, Sun B, Sun Q, Grundy D, Zhang G, Rong W. Curcumin acts via transient receptor potential vanilloid-1 receptors to inhibit gut nociception and reverses visceral hyperalgesia. Neurogastroenterol Motil 2013; 25: e429-e440 [PMID: 23638900 DOI: 10.1111/nmo.12145]
104. Guarino MP, Cheng L, Ma J, Harnett K, Biancani P, Altomare A, Panzera F, Behar J, Cicala M. Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterol Motil 2010; 22: 746-751, e219 [PMID: 20456759 DOI: 10.1111/ j.1365-2982.2010.01514.x]
105. Savarino E, Zentilin P, Tutuian R, Pohl D, Casa DD, Frazzoni M, Cestari R, Savarino V. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008; 103: 2685-2693 [PMID: 18775017 DOI: 10.1111/j.1572-0241.2008.02119.x]
106. Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S, Farahmand BY, Winchester CC, Roda E, Bazzoli F. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008; 57: 1354-1359 [PMID: 18424568 DOI: 10.1136/gut.2007.145177]
107. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702 [PMID: 14988823 DOI: 10.1053/j.gastro.2003.11.055]